Skip to main content
SpringerLink
Log in

Elotuzumab

  • Chapter
  • First Online:
Resistance to Targeted Therapies in Multiple Myeloma

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics ((RTACT,volume 22))

  • 315 Accesses

Abstract

Elotuzumab is approved for therapy in combination with dexamethasone and an immunomodulatory agent in relapsed and refractory myeloma patients. Given its relative recency of use in clinical practice, mechanisms of resistance are poorly understood and will require further study for full elucidation. Nevertheless, this chapter will examine what is known, extrapolate from concepts established in other monoclonal antibodies, and anticipate avenues for future research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ADA:

Anti-drug antibodies

ADCC:

Antibody-dependent cellular cytotoxicity

EMA:

European Medicines Agency

FDA:

US Food and Drug Administration

IgG1:

Immunoglobulin G1

IMiD:

Immunomodulatory imide drug

MM:

Multiple myeloma

MoAb:

Monoclonal antibody

NK:

Natural killer

ORR:

Overall response rate

OS:

Overall survival

PFS:

Progression free survival

RRMM:

Relapsed/refractory multiple myeloma

siRNA:

Small interfering RNA

SLAMF7:

Signaling lymphocytic activation molecule family member 7

References

  1. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–9.

    Article  CAS  Google Scholar 

  2. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.

    Article  CAS  Google Scholar 

  3. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–22.

    Article  CAS  Google Scholar 

  4. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–84.

    Article  CAS  Google Scholar 

  5. Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.

    Article  CAS  Google Scholar 

  6. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–9.

    Article  CAS  Google Scholar 

  7. Balasa B, Yun R, Belmar NA, Fox M, Chao DT, Robbins MD, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015;64(1):61–73.

    Article  CAS  Google Scholar 

  8. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–37.

    Article  CAS  Google Scholar 

  9. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Therap. 2009;8(9):2616–24.

    Article  Google Scholar 

  10. Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959–70.

    Article  CAS  Google Scholar 

  11. Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039–49.

    Article  CAS  Google Scholar 

  12. Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019;25(10):3176–87.

    Article  CAS  Google Scholar 

  13. Danhof S, Strifler S, Hose D, Kortum M, Bittrich M, Hefner J, et al. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. J Cancer Res Clin Oncol. 2019;145(3):561–71.

    Article  CAS  Google Scholar 

  14. Jakubowiak A, Offidani M, Pegourie B, De La Rubia J, Garderet L, Laribi K, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–40.

    Article  CAS  Google Scholar 

  15. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med. 1989;170(2):481–97.

    Article  CAS  Google Scholar 

  16. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell fc gammaRIIIa, independently of the fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109–14.

    Article  CAS  Google Scholar 

  17. Poulart V, Jou YM, Delmonte T, Robbins M. Fc gamma receptor polymorphisms and progression free survival-analysis of three clinical trials of elotuzumab in multiple myeloma. Copenhagen, Denmark: EHA 2018; 2018.

    Google Scholar 

  18. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11(16):5984–92.

    Article  CAS  Google Scholar 

  19. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–9.

    Article  CAS  Google Scholar 

  20. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–5.

    Article  CAS  Google Scholar 

  21. Dimopoulos M, Facon T, Richardson P, Orlowski R, San Miguel J, Lonial S, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). J Clin Oncol. 2017;30

    Google Scholar 

Download references

Acknowledgment

This work was supported by NSW Pathology and the Department of Haematology, Liverpool Hospital.

Author information

Authors and Affiliations

  1. Department of Haematology, Liverpool Hospital, NSW Pathology, Liverpool, NSW, Australia

    Adam Bryant

  2. UNSW, Sydney, Australia

    Adam Bryant

Authors
  1. Adam Bryant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam Bryant .

Editor information

Editors and Affiliations

  1. Department of Haematology, Liverpool Hospital, NSW Pathology, NSW, Australia UNSW, Sydney Australia Western Sydney University, Australia Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia

    Silvia CW Ling

  2. Department of Haematology, Liverpool Hospital, UNSW, Sydney, Australia

    Steven Trieu

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bryant, A. (2021). Elotuzumab. In: Ling, S.C., Trieu, S. (eds) Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Anti-Cancer Therapeutics, vol 22. Springer, Cham. https://doi.org/10.1007/978-3-030-73440-4_6

Download citation

Publish with us

Policies and ethics

Search

Navigation